AbbVie and Genmab shares gain as the EPCORE DLBCL-2 trial demonstrates superior progression-free survival for frontline lymphoma patients using their bispecific antibody combination.
AbbVie's oncology pipeline is significantly bolstered by the EPCORE DLBCL-2 Phase 3 study, which demonstrated that the combination of epcoritamab with standard-of-care chemotherapy achieved statistically significant improvements in progression-free survival for frontline DLBCL patients. This clinical success validates the company's strategic focus on bispecific antibody therapies and provides a clear pathway for upcoming regulatory submissions in the frontline treatment setting.
The study demonstrated statistically significant and clinically meaningful improvement in progression-free survival (PFS) for frontline DLBCL patients.
The positive results from the EPCORE DLBCL-2 trial serve as a critical validation of Genmab's proprietary bispecific antibody platform, which is central to their partnership with AbbVie. By proving the efficacy of epcoritamab in a frontline setting, Genmab strengthens its long-term revenue potential through milestone payments and future commercial royalties associated with the drug's expansion into broader patient populations.
It is the first Phase 3 study of a bispecific antibody combination therapy to show significant PFS improvement in frontline DLBCL, validating Genmab's core technology platform.
AbbVie and Genmab announced that their Phase 3 EPCORE DLBCL-2 study met its primary endpoint, showing significant improvement in progression-free survival for frontline diffuse large B-cell lymphoma patients. This milestone validates the efficacy of their bispecific antibody combination therapy in a challenging oncology setting.
The study is the first to demonstrate that a bispecific antibody combination therapy provides statistically significant and clinically meaningful improvements in progression-free survival for patients with newly diagnosed diffuse large B-cell lymphoma.